Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Avatrombopag, sold under the brand name Doptelet, is a medication that is used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023.
Read the full article on WikipediaSevere thrombocytopenia Clinical criteria: Treatment Phase: Initial treatment - New patient The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP), AND Patient must have failed to achieve an adequate response to, or be intolerant to, corticosteroid therapy, AND Patient must have failed to achieve an adequate response to, or be intolerant to, immunoglobulin therapy, AND The treatment must be the sole PBS-subsidised thrombopoietin receptor agonist (TRA) for this condition. The following criteria indicate failure to achieve an adequate response to corticosteroid and/or immunoglobulin therapy and must be demonstrated at the time of initial application; (a) a platelet count of less than or equal to 20,000 million per L; OR (b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range. The authority application must be made via the online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include: (a) details of a platelet count supporting the diagnosis of ITP. All reports must be documented in the patient's medical records. If the application is submitted through HPOS form upload or mail, it must include: (i) details of the proposed prescription; and (ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). The platelet count must be no more than 4 weeks old at the time of application and must be documented in the patient's medical records. A maximum of 24 weeks of treatment with this drug will be authorised under this criterion.
Working under the parallel aged-care framework? Aged-care equivalent →